Expression of c-met is a strong independent prognostic factor in breast carcinoma

182Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND. The c-met protooncogene encodes the met protein, the receptor for scatter factor/hepatocyte growth factor, a growth factor that modulates the motility and stable interaction of the epithelial cells. This study assesses the expression of met receptor in breast carcinoma and its prognostic value with respect to survival. METHODS. Immunofluorescence was used to evaluate 91 archival breast carcinoma specimens using a polyclonal antibody to the cytoplasmic domain of the receptor. Cases were scored by two pathologists on a percentage basis and then converted to binary scores (positive or negative) on the basis of a bimodal distribution. RESULTS. Strong expression of met was found in 20 invasive ductal breast tumor specimens (22%). The 5-year survival of patients whose tumors showed decreased met expression was 89%, in contrast to a 52% 5-year survival rate in patients whose tumors expressed met (P = 0.008). This trend also was observed in patients without lymph node metastases at presentation, in whom met negative patients had a 95% 5-year survival compared with only 62% for met positive patients (P = 0.006). Multivariate analysis using the Cox proportional hazards model showed met expression to be an independent predictor of survival, with a predictive value nearly equivalent to that associated with lymph node status. CONCLUSIONS. The authors conclude that expression of met in patients with invasive ductal carcinoma of the breast is a strong, independent predictor of decreased survival and may be a useful prognostic marker with which to identify a subset of patients with more aggressive disease.

References Powered by Scopus

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

2254Citations
N/AReaders
Get full text

Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers

791Citations
N/AReaders
Get full text

Emerging multipotent aspects of hepatocyte growth factor

630Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Validation of tissue microarray technology in breast carcinoma

680Citations
N/AReaders
Get full text

Invasive growth: A MET-driven genetic programme for cancer and stem cells

498Citations
N/AReaders
Get full text

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

491Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ghoussoub, R. A. D., Dillon, D. A., D’Aquila, T., Rimm, E. B., Fearon, E. R., & Rimm, D. L. (1998). Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer, 82(8), 1513–1520. https://doi.org/10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7

Readers over time

‘10‘11‘13‘14‘15‘17‘18‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 8

32%

Professor / Associate Prof. 2

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

50%

Agricultural and Biological Sciences 7

27%

Biochemistry, Genetics and Molecular Bi... 4

15%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Save time finding and organizing research with Mendeley

Sign up for free
0